Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01940809
Title Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)



Dabrafenib + Ipilimumab

Ipilimumab + Nivolumab + Trametinib

Dabrafenib + Ipilimumab + Trametinib

Ipilimumab + Trametinib

Dabrafenib + Ipilimumab + Nivolumab


Ipilimumab + Nivolumab

Dabrafenib + Ipilimumab + Nivolumab + Trametinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST